Literature DB >> 22789552

Cytomegalovirus infection in association with early onset pre-eclampsia.

L Higgins1, S Vause, C Tower.   

Abstract

This case describes a woman who presented with raised α-fetoprotein (AFP) on second trimester screening, and developed early onset fetal growth restriction (FGR) and severe pre-eclampsia (PET) before 24 weeks' gestation requiring magnesium sulphate and intravenous antihypertensives. Ultrasonography revealed a structurally normal fetus with estimated weight <3rd centile, abnormal uterine artery Dopplers and deteriorating fetal arterial Dopplers over the following 2 weeks. The pregnancy ended in fetal death before a viable weight was reached. Postmortem examination revealed a growth restricted fetus (birth weight <0.4th centile) and chronic villitis secondary to placental cytomegalovirus (CMV) infection. CMV has previously been associated with PET and FGR. This case highlights its potential role in the pathogenesis of placental failure and has relevance for counselling and management for future pregnancies. Furthermore, raised AFP may represent ongoing placental damage and offers potential for future therapeutic measures--for example, antivirals or immunisations to alter the natural history and prognosis of placental infection.

Entities:  

Mesh:

Year:  2010        PMID: 22789552      PMCID: PMC3030220          DOI: 10.1136/bcr.03.2010.2803

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  31 in total

1.  Recognition of the long-term sequelae of eclampsia.

Authors:  L C Chesley
Journal:  Am J Obstet Gynecol       Date:  2000-01       Impact factor: 8.661

2.  Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births.

Authors:  G C Smith; J P Pell; D Walsh
Journal:  Lancet       Date:  2001-06-23       Impact factor: 79.321

3.  Long-term prognosis of hypertension in pregnancy.

Authors:  R Marín; M Gorostidi; C G Portal; M Sánchez; E Sánchez; J Alvarez
Journal:  Hypertens Pregnancy       Date:  2000       Impact factor: 2.108

4.  Acute rejection, cytomegalovirus infection and endothelial dysfunction early after heart transplantation.

Authors:  M Sabaté; N Manito; A Cequier; J Roca; J Mauri; F Jara; J A Gomez-Hospital; A Ruiz-Majoral; J Sala; P Alcaide
Journal:  Transplant Proc       Date:  1995-08       Impact factor: 1.066

5.  The remote prognosis of eclamptic women. Sixth periodic report.

Authors:  L C Chesley; J E Annitto; R A Cosgrove
Journal:  Am J Obstet Gynecol       Date:  1976-03-01       Impact factor: 8.661

6.  Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: implications for transmission and pathogenesis.

Authors:  S Fisher; O Genbacev; E Maidji; L Pereira
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 7.  Fetal effects of primary and secondary cytomegalovirus infection in pregnancy.

Authors:  Asher Ornoy; Orna Diav-Citrin
Journal:  Reprod Toxicol       Date:  2006-05       Impact factor: 3.143

8.  Preeclampsia: a multifactorial disease resulting from the interaction of the feto-maternal HLA genotype and HCMV infection.

Authors:  M Carreiras; S Montagnani; Z Layrisse
Journal:  Am J Reprod Immunol       Date:  2002-09       Impact factor: 3.886

9.  Significance of elevated mid-trimester maternal plasma-alpha-fetoprotein values.

Authors:  D J Brock; L Barron; P Duncan; J B Scrimgeour; M Watt
Journal:  Lancet       Date:  1979-06-16       Impact factor: 79.321

10.  Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study.

Authors:  Sonia Hernández-Díaz; Sengwee Toh; Sven Cnattingius
Journal:  BMJ       Date:  2009-06-18
View more
  1 in total

1.  Lack of Association Between Cytomegalovirus Infection and Hypertensive Disorders in Pregnancy: A Case-Control Study in Durango, Mexico.

Authors:  Cosme Alvarado-Esquivel; Ada A Sandoval-Carrillo; Fernando Vazquez-Alaniz; José M Salas-Pacheco; Jesús Hernández-Tinoco; Luis Francisco Sánchez-Anguiano; Elizabeth Irasema Antuna-Salcido
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2017-07-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.